ArticleNAR genomics and bioinformatics2026
Accelerating rare disease diagnostics by linking DNA and RNA through an explainable and interactive RNA-guided workflow.
Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multidisciplinary RNA-guided approach to complement genomic analysis of unsolved patients with an inborn error of immunity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Challenges preventing mainstream use of RNA-sequencing (RNA-seq) in genome diagnostics are sources of biological and technical variation, typically caused by intrinsic differences in gene expression between tissue types, cellular conditions, and environmental factors. While machine learning methods may partially correct unwanted variation, interpreting RNA-seq data that are typically generated by different sources over time, which is a realistic scenario in healthcare, remains challenging and complex. We developed a complete RNA-guided workflow that handles such variation and is therefore able to identify gene-disease associations in the context of genomic, phenotypic, and segregation analysis of rare disease patients. The result is a streamlined implementation of OUTRIDER and FRASER, complemented with Borzoi and MOLGENIS VIP. This novel workflow paves the way for pinpointing rare variants affecting gene expression and splicing using self-contained interactive reports visualizing outlier genes and prioritized patient-level variants for immediate clinical interpretation. We analysed 144 cases from different centres, a realistic cohort for centres more likely to be dependent on background cohorts. We demonstrate that RNA outlier analysis enhances variant interpretation and, despite its limitations, is already able to aid clinical variant interpretation. Our workflow accelerates the prioritization of coding and non-coding variants, and the reclassification of clinically relevant variants of unknown significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.